Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors
  • Directors' shareholdings
  • Financial calendar
  • Annual reports
  • Financial highlights
  • Strategy
  • Investor contacts
  • Corporate governance
  • Shareholder information
  • Investor tools
  • SEC filings
  • Financial results
  • Presentations & webcasts
  • FAQs

You are here

• Home

• Investor relations

• Latest news collapse

  • 16 November 2009 BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI)

    AstraZeneca today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty, a procedure termed primary Percutaneous Coronary Intervention or “PCI,” in order to restore flow, salvage the heart muscle (myocardium) from infarction and reduce mortality.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

  Share price tools collapse

  • Interactive stock charts
  • Share holding calculator
  • Share price look-up
  • Share price history

• Annual Report 2008 collapse

  • Online annual report
  • Order a printed copy

  Latest presentation collapse

  November 2009

  • Investor Relations general presentation (PDF 3 Mb)

  • Other presentations

  Financial results collapse

  Third Quarter & Nine Months results 2009 announced Thursday, 29 October 2009.

  • View details of the event
  • View financial calendar

  Managing your shares collapse

  • Dividend information
  • Shareholder forms
  • Share registration contacts
  • Annual General Meeting
  • FAQs

  Currency Guidance 2009 expand

Not signed in

Page tools

• Print
• Bookmark this page

Share price